{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T14:51:10Z","timestamp":1783003870393,"version":"3.54.5"},"reference-count":161,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s12035-025-05493-1","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T11:10:51Z","timestamp":1764760251000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Unveiling the Neuroprotective Effect of Paraoxonase 1 in Neurodegenerative Diseases Focusing on Alzheimer\u2019s Disease"],"prefix":"10.1007","volume":"63","author":[{"given":"Alaa","family":"Ismail","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayder M.","family":"Al-kuraishy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali I.","family":"Al-Gareeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Alexiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9020-874X","authenticated-orcid":false,"given":"Marios","family":"Papadakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1827-6131","authenticated-orcid":false,"given":"Safaa A.","family":"Faheem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7817-425X","authenticated-orcid":false,"given":"Gaber El-Saber","family":"Batiha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"issue":"3","key":"5493_CR1","doi-asserted-by":"publisher","first-page":"113","DOI":"10.4103\/japtr.JAPTR_298_18","volume":"9","author":"MS Al-Naimi","year":"2018","unstructured":"Al-Naimi MS et al (2018) Levothyroxine improves paraoxonase (PON-1) serum levels in patients with primary hypothyroidism: case\u2013control study. J Adv Pharm Technol Res 9(3):113\u2013118","journal-title":"J Adv Pharm Technol Res"},{"issue":"24","key":"5493_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25245980","volume":"25","author":"A Taler-Ver\u010di\u010d","year":"2020","unstructured":"Taler-Ver\u010di\u010d A, Goli\u010dnik M, Bavec A (2020) The structure and function of paraoxonase-1 and its comparison to paraoxonase-2 and-3. Molecules 25(24):5980","journal-title":"Molecules"},{"key":"5493_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2020.108067","volume":"161","author":"Y Shokri","year":"2020","unstructured":"Shokri Y et al (2020) Importance of paraoxonase 1 (PON1) as an antioxidant and antiatherogenic enzyme in the cardiovascular complications of type 2 diabetes: genotypic and phenotypic evaluation. Diabetes Res Clin Pract 161:108067","journal-title":"Diabetes Res Clin Pract"},{"issue":"12","key":"5493_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/biom9120817","volume":"9","author":"K Priyanka","year":"2019","unstructured":"Priyanka K, Singh S, Gill K (2019) Paraoxonase 3: structure and its role in pathophysiology of coronary artery disease. Biomolecules 9(12):817","journal-title":"Biomolecules"},{"issue":"3","key":"5493_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11030590","volume":"11","author":"CJ Mohammed","year":"2022","unstructured":"Mohammed CJ et al (2022) A PON for all seasons: comparing paraoxonase enzyme substrates, activity and action including the role of PON3 in health and disease. Antioxidants 11(3):590","journal-title":"Antioxidants"},{"key":"5493_CR6","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1007\/s00580-019-02990-3","volume":"28","author":"J Hussein","year":"2019","unstructured":"Hussein J et al (2019) Synthesis of docosahexaenoic acid\u2013loaded zinc oxide nanoparticles as a promising treatment in neurotoxicity. Comp Clin Pathol 28:1455\u20131464","journal-title":"Comp Clin Pathol"},{"issue":"9","key":"5493_CR7","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1089\/dna.2020.5416","volume":"39","author":"Z Chen","year":"2020","unstructured":"Chen Z et al (2020) Assessment of PPARGC1A, PPARGC1B, and PON1 genetic polymorphisms in esophageal squamous cell carcinoma susceptibility in the Eastern Chinese Han population: a case\u2013control study involving 2351 subjects. DNA Cell Biol 39(9):1521\u20131531","journal-title":"DNA Cell Biol"},{"issue":"1-2","key":"5493_CR8","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/0014-5793(91)80962-3","volume":"286","author":"MI Mackness","year":"1991","unstructured":"Mackness MI, Arrol S, Durrington PN (1991) Paraoxonase prevents accumulation of lipoperoxides in low\u2010density lipoprotein. FEBS Lett 286(1\u20132):152\u2013154. https:\/\/doi.org\/10.1016\/0014-5793(91)80962-3","journal-title":"FEBS Lett"},{"issue":"7","key":"5493_CR9","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1080\/07388551.2021.1898331","volume":"41","author":"W Xu","year":"2021","unstructured":"Xu W et al (2021) Recent advances and future prospective of organophosphorus-degrading enzymes: identification, modification, and application. Crit Rev Biotechnol 41(7):1096\u20131113","journal-title":"Crit Rev Biotechnol"},{"issue":"2","key":"5493_CR10","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/biof.1549","volume":"46","author":"J Kotur-Stevuljevi\u0107","year":"2020","unstructured":"Kotur-Stevuljevi\u0107 J et al (2020) Paraoxonase 1 and atherosclerosis-related diseases. BioFactors 46(2):193\u2013205","journal-title":"BioFactors"},{"issue":"5","key":"5493_CR11","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3390\/antiox8050118","volume":"8","author":"D Levy","year":"2019","unstructured":"Levy D, Reichert CO, Bydlowski SP (2019) Paraoxonases activities and polymorphisms in elderly and old-age diseases: an overview. Antioxidants 8(5):118","journal-title":"Antioxidants"},{"key":"5493_CR12","doi-asserted-by":"crossref","unstructured":"Sreelatha S et al\u00a0(2022) Role of oxidant-antioxidant enzymes in managing the cardiovascular risks in nephrotic syndrome patients.\u00a0J Nephropathol 11(2)","DOI":"10.34172\/jnp.2022.17276"},{"key":"5493_CR13","doi-asserted-by":"crossref","unstructured":"Qin S\u00a0(2020) LDL and HDL oxidative modification and atherosclerosis. Lipid transfer in lipoprotein metabolism and cardiovascular disease p 157\u2013169","DOI":"10.1007\/978-981-15-6082-8_10"},{"issue":"3","key":"5493_CR14","doi-asserted-by":"publisher","first-page":"292","DOI":"10.4103\/ijmr.ijmr_1212_22","volume":"158","author":"H Thakkar","year":"2023","unstructured":"Thakkar H et al (2023) High density lipoprotein heterogeneity & function among Indians with coronary artery disease. Indian J Med Res 158(3):292\u2013302","journal-title":"Indian J Med Res"},{"issue":"2","key":"5493_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21020601","volume":"21","author":"J Rysz","year":"2020","unstructured":"Rysz J et al (2020) The role and function of HDL in patients with chronic kidney disease and the risk of cardiovascular disease. Int J Mol Sci 21(2):601","journal-title":"Int J Mol Sci"},{"issue":"2","key":"5493_CR16","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.freeradbiomed.2008.03.023","volume":"45","author":"J Marsillach","year":"2008","unstructured":"Marsillach J et al (2008) Immunohistochemical analysis of paraoxonases-1, 2, and 3 expression in normal mouse tissues. Free Radic Biol Med 45(2):146\u2013157","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"5493_CR17","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6677111","volume":"2021","author":"Y Xu","year":"2021","unstructured":"Xu Y et al (2021) The antioxidant enzyme PON1: a potential prognostic predictor of acute ischemic stroke. Oxid Med Cell Longev 2021(1):6677111","journal-title":"Oxid Med Cell Longev"},{"key":"5493_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2023.102075","volume":"91","author":"HM Al-Kuraishy","year":"2023","unstructured":"Al-Kuraishy HM, Jabir MS, Al-Gareeb AI, Albuhadily AK (2023) The conceivable role of prolactin hormone in Parkinson disease: the same goal but with different ways. Ageing Res Rev 91:102075. https:\/\/doi.org\/10.1016\/j.arr.2023.102075","journal-title":"Ageing Res Rev"},{"issue":"6","key":"5493_CR19","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1007\/s11011-023-01254-y","volume":"38","author":"HM Al-Kuraishy","year":"2023","unstructured":"Al-Kuraishy HM et al (2023) New insights on the potential effect of vinpocetine in Parkinson\u2019s disease: one of the neglected warden and baffling topics. Metab Brain Dis 38(6):1831\u20131840","journal-title":"Metab Brain Dis"},{"key":"5493_CR20","doi-asserted-by":"publisher","first-page":"121532","DOI":"10.1016\/j.lfs.2023.121532","volume":"320","author":"HM Al-Kuraishy","year":"2023","unstructured":"Al-Kuraishy HM, Al-Gareeb AI, Alsayegh AA, Abusudah WF, Almohmadi NH, Eldahshan OA, Ahmed EA, Batiha G-S (2023) Insights on benzodiazepines\u2019 potential in Alzheimer\u2019s disease. Life Sci 320:121532. https:\/\/doi.org\/10.1016\/j.lfs.2023.121532","journal-title":"Life Sci"},{"issue":"3","key":"5493_CR21","first-page":"66","volume":"28","author":"A Mota","year":"2019","unstructured":"Mota A et al (2019) Association of paraoxonse1 (PON1) genotypes with the activity of PON1 in patients with Parkinson\u2019s disease. Acta Neurol Taiwan 28(3):66\u201374","journal-title":"Acta Neurol Taiwan"},{"issue":"1","key":"5493_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15761\/JBN.1000120","volume":"4","author":"A Mota","year":"2019","unstructured":"Mota A, Taheraghdam A, Valilo M (2019) Paraoxonase1 and its relationship with Parkinson\u2019s disease. Brain 4(1):1\u20136. https:\/\/doi.org\/10.15761\/JBN.1000120","journal-title":"Brain"},{"issue":"2","key":"5493_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/antiox12020399","volume":"12","author":"B Petri\u010d","year":"2023","unstructured":"Petri\u010d B et al (2023) Investigation of paraoxonase-1 genotype and enzyme-kinetic parameters in the context of cognitive impairment in Parkinson\u2019s disease. Antioxidants 12(2):399","journal-title":"Antioxidants"},{"issue":"3","key":"5493_CR24","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.jocn.2013.04.025","volume":"21","author":"A Kirbas","year":"2014","unstructured":"Kirbas A et al (2014) Paraoxonase and arylesterase activity and total oxidative\/anti-oxidative status in patients with idiopathic Parkinson\u2019s disease. J Clin Neurosci 21(3):451\u2013455","journal-title":"J Clin Neurosci"},{"issue":"4","key":"5493_CR25","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1159\/000323265","volume":"8","author":"K Ikeda","year":"2011","unstructured":"Ikeda K et al (2011) Serological profiles of urate, paraoxonase-1, ferritin and lipid in Parkinson\u2019s disease: changes linked to disease progression. Neurodegener Dis 8(4):252\u2013258","journal-title":"Neurodegener Dis"},{"issue":"3","key":"5493_CR26","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1096\/fj.04-2106fje","volume":"19","author":"L Benmoyal-Segal","year":"2005","unstructured":"Benmoyal-Segal L et al (2005) Acetylcholinesterase\/paraoxonase interactions increase the risk of insecticide-induced Parkinson\u2019s disease. FASEB J 19(3):452\u2013454","journal-title":"FASEB J"},{"key":"5493_CR27","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.neulet.2016.02.011","volume":"617","author":"CC de Farias","year":"2016","unstructured":"de Farias CC, Maes M, Bonif\u00e1cio KL, Bortolasci CC, de Souza Nogueira A, Brinholi FF, Matsumoto AK, do Nascimento MA, de Melo LB, Nixdorf SL, Lavado EL, Moreira EG, Barbosa DS (2016) Highly specific changes in antioxidant levels and lipid peroxidation in Parkinson\u2019s disease and its progression: disease and staging biomarkers and new drug targets. Neurosci Lett 617:66\u201371. https:\/\/doi.org\/10.1016\/j.neulet.2016.02.011","journal-title":"Neurosci Lett"},{"issue":"10360","key":"5493_CR28","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/S0140-6736(22)01272-7","volume":"400","author":"EL Feldman","year":"2022","unstructured":"Feldman EL et al (2022) Amyotrophic lateral sclerosis. Lancet 400(10360):1363\u20131380","journal-title":"Lancet"},{"issue":"10","key":"5493_CR29","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1111\/ene.14393","volume":"27","author":"P Masrori","year":"2020","unstructured":"Masrori P, Van Damme P (2020) Amyotrophic lateral sclerosis: a clinical review. Eur J Neurol 27(10):1918\u20131929","journal-title":"Eur J Neurol"},{"issue":"5","key":"5493_CR30","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1097\/WCO.0000000000001098","volume":"35","author":"K Del Tredici","year":"2022","unstructured":"Del Tredici K, Braak H (2022) Neuropathology and neuroanatomy of TDP-43 amyotrophic lateral sclerosis. Curr Opin Neurol 35(5):660\u2013671","journal-title":"Curr Opin Neurol"},{"issue":"5","key":"5493_CR31","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1097\/WCO.0b013e328356d328","volume":"25","author":"AC Ludolph","year":"2012","unstructured":"Ludolph AC, Brettschneider J, Weishaupt JH (2012) Amyotrophic lateral sclerosis. Curr Opin Neurol 25(5):530\u2013535","journal-title":"Curr Opin Neurol"},{"issue":"1","key":"5493_CR32","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/ana.21993","volume":"68","author":"N Ticozzi","year":"2010","unstructured":"Ticozzi N et al (2010) Paraoxonase gene mutations in amyotrophic lateral sclerosis. Ann Neurol 68(1):102\u2013107","journal-title":"Ann Neurol"},{"issue":"2","key":"5493_CR33","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1089\/jmf.2012.2509","volume":"16","author":"M Mohammadshahi","year":"2013","unstructured":"Mohammadshahi M, Haidari F, Saei AA, Rashidi B, Mahboob S, Rashidi M-R (2013) Soy protein, genistein, and daidzein improve serum paraoxonase activity and lipid profiles in rheumatoid arthritis in rats. J Med Food 16(2):147\u2013154. https:\/\/doi.org\/10.1089\/jmf.2012.2509","journal-title":"J Med Food"},{"issue":"1\u20132","key":"5493_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10528-010-9376-6","volume":"49","author":"MA Ergun","year":"2011","unstructured":"Ergun MA et al (2011) PON1 55 and 192 gene polymorphisms in type 2 diabetes mellitus patients in a Turkish population. Biochem Genet 49(1\u20132):1\u20138","journal-title":"Biochem Genet"},{"issue":"9","key":"5493_CR35","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1136\/jnnp.2006.112581","volume":"78","author":"S Cronin","year":"2007","unstructured":"Cronin S et al (2007) Paraoxonase promoter and intronic variants modify risk of sporadic amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 78(9):984\u2013986","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"5493_CR36","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1212\/01.wnl.0000305956.37931.dd","volume":"70","author":"A-M Wills","year":"2008","unstructured":"Wills A-M et al (2008) Paraoxonase 1 (PON1) organophosphate hydrolysis is not reduced in ALS. Neurology 70(12):929\u2013934","journal-title":"Neurology"},{"key":"5493_CR37","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1007\/s10072-019-03834-2","volume":"40","author":"F Verde","year":"2019","unstructured":"Verde F et al (2019) PON1 is a disease modifier gene in amyotrophic lateral sclerosis: association of the Q192R polymorphism with bulbar onset and reduced survival. Neurol Sci 40:1469\u20131473","journal-title":"Neurol Sci"},{"issue":"16","key":"5493_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23169339","volume":"23","author":"A Motataianu","year":"2022","unstructured":"Motataianu A et al (2022) Oxidative stress in amyotrophic lateral sclerosis: synergy of genetic and environmental factors. Int J Mol Sci 23(16):9339","journal-title":"Int J Mol Sci"},{"issue":"1","key":"5493_CR39","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.0b013e3181a18674","volume":"73","author":"A-M Wills","year":"2009","unstructured":"Wills A-M et al (2009) A large-scale international meta-analysis of paraoxonase gene polymorphisms in sporadic ALS. Neurology 73(1):16\u201324","journal-title":"Neurology"},{"issue":"11","key":"5493_CR40","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1007\/s11064-023-03981-1","volume":"48","author":"M Alruwaili","year":"2023","unstructured":"Alruwaili M et al (2023) Pathogenic role of fibrinogen in the neuropathology of multiple sclerosis: a tale of sorrows and fears. Neurochem Res 48(11):3255\u20133269","journal-title":"Neurochem Res"},{"key":"5493_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.1025659","volume":"13","author":"C Hollen","year":"2023","unstructured":"Hollen C et al (2023) Oxidative stress in multiple sclerosis\u2014emerging imaging techniques. Front Neurol 13:1025659","journal-title":"Front Neurol"},{"key":"5493_CR42","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s12017-009-8095-9","volume":"12","author":"C Mart\u00ednez","year":"2010","unstructured":"Mart\u00ednez C et al (2010) Paraoxonase 1 polymorphisms are not related with the risk for multiple sclerosis. Neuromol Med 12:217\u2013223","journal-title":"Neuromol Med"},{"issue":"3","key":"5493_CR43","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1177\/1352458508098371","volume":"15","author":"A Jamroz-Wisniewska","year":"2009","unstructured":"Jamroz-Wisniewska A et al (2009) Paraoxonase 1 activity in different types of multiple sclerosis. Mult Scler J 15(3):399\u2013402","journal-title":"Mult Scler J"},{"issue":"3","key":"5493_CR44","doi-asserted-by":"publisher","first-page":"744","DOI":"10.3390\/nu12030744","volume":"12","author":"E Drehmer","year":"2020","unstructured":"Drehmer E et al (2020) The relation between eating habits and abdominal fat, anthropometry, PON1 and IL-6 levels in patients with multiple sclerosis. Nutrients 12(3):744","journal-title":"Nutrients"},{"issue":"8","key":"5493_CR45","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1111\/ene.15826","volume":"30","author":"C Essenburg","year":"2023","unstructured":"Essenburg C et al (2023) Antioxidant defense enzymes in multiple sclerosis: a 5-year follow-up study. Eur J Neurol 30(8):2338\u20132347","journal-title":"Eur J Neurol"},{"key":"5493_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2023.102084","volume":"91","author":"HM Al-Kuraishy","year":"2023","unstructured":"Al-Kuraishy HM, Jabir MS, Albuhadily AK, Al-Gareeb AI, Rafeeq MF (2023) The link between metabolic syndrome and Alzheimer disease: a mutual relationship and long rigorous investigation. Ageing Res Rev 91:102084. https:\/\/doi.org\/10.1016\/j.arr.2023.102084","journal-title":"Ageing Res Rev"},{"issue":"5","key":"5493_CR47","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s11011-025-01649-z","volume":"40","author":"GH Alshehri","year":"2025","unstructured":"Alshehri GH et al (2025) Tirzepatide: a novel therapeutic approach for Alzheimer\u2019s disease. Metab Brain Dis 40(5):221","journal-title":"Metab Brain Dis"},{"issue":"7","key":"5493_CR48","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.1007\/s10571-023-01392-y","volume":"43","author":"FH AlAnazi","year":"2023","unstructured":"AlAnazi FH et al (2023) Primary hypothyroidism and Alzheimer\u2019s disease: a tale of two. Cell Mol Neurobiol 43(7):3405\u20133416","journal-title":"Cell Mol Neurobiol"},{"issue":"2","key":"5493_CR49","doi-asserted-by":"publisher","first-page":"e17993","DOI":"10.1111\/jcmm.17993","volume":"28","author":"NH Ali","year":"2024","unstructured":"Ali NH, Al-Kuraishy HM, Al-Gareeb AI, Alnaaim SA, Alexiou A, Papadakis M, Khalifa AA, Saad HM et al (2024) Neprilysin inhibitors and risk of Alzheimer\u2019s disease: a future perspective. J Cell Mol Med 28(2):e17993. https:\/\/doi.org\/10.1111\/jcmm.17993","journal-title":"J Cell Mol Med"},{"issue":"10","key":"5493_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci12101290","volume":"12","author":"N Alsubaie","year":"2022","unstructured":"Alsubaie N et al (2022) Statins use in Alzheimer disease: bane or boon from frantic search and narrative review. Brain Sci 12(10):1290","journal-title":"Brain Sci"},{"issue":"1","key":"5493_CR51","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s12017-025-08857-x","volume":"27","author":"SM Alqahtani","year":"2025","unstructured":"Alqahtani SM, Al-kuraishy HM, Al Gareeb AI, Albuhadily AK, Alexiou A, Papadakis M, Hemeda LR, Faheem SA et al (2025) Unlocking Alzheimer\u2019s disease: the role of BDNF signaling in neuropathology and treatment. Neuromol Med 27(1):36. https:\/\/doi.org\/10.1007\/s12017-025-08857-x","journal-title":"Neuromol Med"},{"issue":"1","key":"5493_CR52","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13098-023-01082-1","volume":"15","author":"M Alrouji","year":"2023","unstructured":"Alrouji M et al (2023) The potential role of human islet amyloid polypeptide in type 2 diabetes mellitus and Alzheimer\u2019s diseases. Diabetol Metab Syndr 15(1):101","journal-title":"Diabetol Metab Syndr"},{"key":"5493_CR53","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-025-05126-7","author":"GH Alshehri","year":"2025","unstructured":"Alshehri GH et al (2025) The AMPK\/GDF15 axis: a novel target for the neuroprotective effects of metformin in ischemic stroke. Mol Neurobiol. https:\/\/doi.org\/10.1007\/s12035-025-05126-7","journal-title":"Mol Neurobiol"},{"issue":"2","key":"5493_CR54","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s13760-023-02403-x","volume":"124","author":"NH Ali","year":"2024","unstructured":"Ali NH et al (2024) The probable role of tissue plasminogen activator\/neuroserpin axis in Alzheimer\u2019s disease: a new perspective. Acta Neurol Belg 124(2):377\u2013388","journal-title":"Acta Neurol Belg"},{"issue":"7","key":"5493_CR55","doi-asserted-by":"publisher","first-page":"552","DOI":"10.2174\/1570159X18666200122122512","volume":"18","author":"H Birla","year":"2020","unstructured":"Birla H et al (2020) Role of oxidative stress and metal toxicity in the progression of Alzheimer\u2019s disease. Curr Neuropharmacol 18(7):552\u2013562","journal-title":"Curr Neuropharmacol"},{"key":"5493_CR56","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s40263-019-00619-1","volume":"33","author":"MJ Sharman","year":"2019","unstructured":"Sharman MJ et al (2019) Targeting inflammatory pathways in Alzheimer\u2019s disease: a focus on natural products and phytomedicines. CNS Drugs 33:457\u2013480","journal-title":"CNS Drugs"},{"issue":"1","key":"5493_CR57","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/med.21624","volume":"40","author":"L Zhang","year":"2020","unstructured":"Zhang L et al (2020) Advance of sporadic Alzheimer\u2019s disease animal models. Med Res Rev 40(1):431\u2013458","journal-title":"Med Res Rev"},{"issue":"3","key":"5493_CR58","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.bbrc.2019.05.131","volume":"515","author":"N Izuo","year":"2019","unstructured":"Izuo N et al (2019) An App knock-in mouse inducing the formation of a toxic conformer of A\u03b2 as a model for evaluating only oligomer-induced cognitive decline in Alzheimer\u2019s disease. Biochem Biophys Res Commun 515(3):462\u2013467","journal-title":"Biochem Biophys Res Commun"},{"key":"5493_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40035-020-00195-1","volume":"9","author":"Y Cheng","year":"2020","unstructured":"Cheng Y, Tian D-Y, Wang Y-J (2020) Peripheral clearance of brain-derived A\u03b2 in Alzheimer\u2019s disease: pathophysiology and therapeutic perspectives. Transl Neurodegener 9:1\u201311","journal-title":"Transl Neurodegener"},{"issue":"8","key":"5493_CR60","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1161\/ATVBAHA.108.163998","volume":"28","author":"A Singh-Manoux","year":"2008","unstructured":"Singh-Manoux A et al (2008) Low HDL cholesterol is a risk factor for deficit and decline in memory in midlife: the Whitehall II study. Arterioscler Thromb Vasc Biol 28(8):1556\u20131562","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"5493_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/antiox10030339","volume":"10","author":"JG Salazar","year":"2021","unstructured":"Salazar JG et al (2021) Paraoxonase-1 and-3 protein expression in the brain of the Tg2576 mouse model of Alzheimer\u2019s disease. Antioxidants 10(3):339","journal-title":"Antioxidants"},{"issue":"9","key":"5493_CR62","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1007\/s00204-019-02538-y","volume":"93","author":"M Simunkova","year":"2019","unstructured":"Simunkova M et al (2019) Management of oxidative stress and other pathologies in Alzheimer\u2019s disease. Arch Toxicol 93(9):2491\u20132513","journal-title":"Arch Toxicol"},{"issue":"1\u20132","key":"5493_CR63","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jns.2009.02.317","volume":"283","author":"H Wehr","year":"2009","unstructured":"Wehr H et al (2009) Paraoxonase activity and dementia. J Neurol Sci 283(1\u20132):107\u2013108","journal-title":"J Neurol Sci"},{"key":"5493_CR64","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s004060200013","volume":"252","author":"G Paragh","year":"2002","unstructured":"Paragh G et al (2002) Serum paraoxonase activity changes in patients with Alzheimer\u2019s disease and vascular dementia. Eur Arch Psychiatry Clin Neurosci 252:63\u201367","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"3","key":"5493_CR65","first-page":"238","volume":"110","author":"C Cervellati","year":"2018","unstructured":"Cervellati C et al (2018) Evaluating the link between paraoxonase-1 levels and Alzheimer\u2019s disease development. Minerva Med 110(3):238","journal-title":"Minerva Med"},{"issue":"3","key":"5493_CR66","doi-asserted-by":"publisher","first-page":"238","DOI":"10.23736\/S0026-4806.18.05875-5","volume":"110","author":"C Cervellati","year":"2019","unstructured":"Cervellati C et al (2019) Evaluating the link between paraoxonase-1 levels and Alzheimer\u2019s disease development. Minerva Med 110(3):238\u2013250","journal-title":"Minerva Med"},{"issue":"7","key":"5493_CR67","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1515\/cclm-2014-0803","volume":"53","author":"C Cervellati","year":"2015","unstructured":"Cervellati C et al (2015) PON-1 and ferroxidase activities in older patients with mild cognitive impairment, late onset Alzheimer\u2019s disease or vascular dementia. Clin Chem Lab Med (CCLM) 53(7):1049\u20131056","journal-title":"Clin Chem Lab Med (CCLM)"},{"key":"5493_CR68","doi-asserted-by":"publisher","DOI":"10.2174\/1874091X01711010047","volume":"11","author":"M Saeidi","year":"2017","unstructured":"Saeidi M et al (2017) Alzheimer\u2019s disease and paraoxonase 1 (pon1) gene polymorphisms. The open biochemistry journal 11:47","journal-title":"The open biochemistry journal"},{"key":"5493_CR69","doi-asserted-by":"publisher","first-page":"24946","DOI":"10.1007\/s11356-019-05696-9","volume":"26","author":"M del Carmen Xotlanihua-Gervacio","year":"2019","unstructured":"del Carmen Xotlanihua-Gervacio M et al (2019) Relationship between internal and external factors and the activity of PON1. Environ Sci Pollut Res 26:24946\u201324957","journal-title":"Environ Sci Pollut Res"},{"issue":"1","key":"5493_CR70","doi-asserted-by":"publisher","first-page":"204. e13","DOI":"10.1016\/j.neurobiolaging.2010.08.010","volume":"33","author":"TS Wingo","year":"2012","unstructured":"Wingo TS et al (2012) Paraoxonase-1 polymorphisms in Alzheimer\u2019s disease, Parkinson\u2019s disease, and AD-PD spectrum diseases. Neurobiol Aging 33(1):204. e13-204. e15","journal-title":"Neurobiol Aging"},{"issue":"14","key":"5493_CR71","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1097\/00029330-200607020-00013","volume":"119","author":"X-M He","year":"2006","unstructured":"He X-M et al (2006) Gln192Arg polymorphism in paraoxonase 1 gene is associated with Alzheimer disease in a Chinese Han ethnic population. Chin Med J 119(14):1204\u20131209","journal-title":"Chin Med J"},{"issue":"3\u20134","key":"5493_CR72","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1159\/000113709","volume":"5","author":"V Leduc","year":"2008","unstructured":"Leduc V, Poirier J (2008) Polymorphisms at the paraoxonase 1 L55M and Q192R loci affect the pathophysiology of Alzheimer\u2019s disease: emphasis on the cholinergic system and beta-amyloid levels. Neurodegener Dis 5(3\u20134):225\u2013227","journal-title":"Neurodegener Dis"},{"issue":"2","key":"5493_CR73","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.neulet.2012.06.071","volume":"523","author":"Y Pi","year":"2012","unstructured":"Pi Y et al (2012) Lack of an association between paraoxonase 1 gene polymorphisms (Q192R, L55M) and Alzheimer\u2019s disease: a meta-analysis. Neurosci Lett 523(2):174\u2013179","journal-title":"Neurosci Lett"},{"issue":"1","key":"5493_CR74","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3233\/JAD-143096","volume":"46","author":"T Bacchetti","year":"2015","unstructured":"Bacchetti T, Vignini A, Giulietti A, Nanetti L, Provinciali L, Luzzi S, Mazzanti L, Ferretti G (2015) Higher levels of oxidized low density lipoproteins in Alzheimer\u2019s disease patients: roles for platelet activating factor acetyl hydrolase and paraoxonase-1. J Alzheimers Dis 46(1):179\u2013186. https:\/\/doi.org\/10.3233\/JAD-143096","journal-title":"J Alzheimers Dis"},{"issue":"1\u20132","key":"5493_CR75","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.cca.2008.12.019","volume":"402","author":"K Huen","year":"2009","unstructured":"Huen K et al (2009) Validation of PON1 enzyme activity assays for longitudinal studies. Clin Chim Acta 402(1\u20132):67\u201374","journal-title":"Clin Chim Acta"},{"key":"5493_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2023.110601","volume":"382","author":"M Zuin","year":"2023","unstructured":"Zuin M et al (2023) Paraoxonase 1 activity in patients with Alzheimer disease: systematic review and meta-analysis. Chem Biol Interact 382:110601","journal-title":"Chem Biol Interact"},{"issue":"3","key":"5493_CR77","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/j.1365-2362.2010.02411.x","volume":"41","author":"J Marsillach","year":"2011","unstructured":"Marsillach J et al (2011) Immunohistochemical analysis of paraoxonases-1 and 3 in human atheromatous plaques. Eur J Clin Invest 41(3):308\u2013314","journal-title":"Eur J Clin Invest"},{"issue":"5","key":"5493_CR78","doi-asserted-by":"publisher","first-page":"e861","DOI":"10.1002\/iid3.861","volume":"11","author":"HM Al\u2010kuraishy","year":"2023","unstructured":"Al\u2010kuraishy HM, Hussien NR, Al\u2010Niemi MS, Fahad EH, Al\u2010Buhadily AK, Al\u2010Gareeb AI, Al\u2010Hamash SM, Tsagkaris C et al (2023) SARS\u2010CoV\u20102 induced HDL dysfunction may affect the host\u2019s response to and recovery from COVID\u201019. Immun Inflamm Dis 11(5):e861. https:\/\/doi.org\/10.1002\/iid3.861","journal-title":"Immun Inflamm Dis"},{"issue":"1","key":"5493_CR79","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s12035-023-03561-y","volume":"61","author":"SA Alnaaim","year":"2024","unstructured":"Alnaaim SA et al (2024) Role of brain liver X receptor in Parkinson\u2019s disease: hidden treasure and emerging opportunities. Mol Neurobiol 61(1):341\u2013357","journal-title":"Mol Neurobiol"},{"issue":"2","key":"5493_CR80","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/jnc.15170","volume":"159","author":"S Pedrini","year":"2021","unstructured":"Pedrini S et al (2021) High-density lipoprotein-related cholesterol metabolism in Alzheimer\u2019s disease. J Neurochem 159(2):343\u2013377","journal-title":"J Neurochem"},{"issue":"49","key":"5493_CR81","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abb8680","volume":"6","author":"X Zhang","year":"2020","unstructured":"Zhang X et al (2020) Oligodendroglial glycolytic stress triggers inflammasome activation and neuropathology in Alzheimer\u2019s disease. Sci Adv 6(49):eabb8680","journal-title":"Sci Adv"},{"key":"5493_CR82","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29245955","author":"T Bacchetti","year":"2024","unstructured":"Bacchetti T et al (2024) Effect of diet on HDL in obesity. Molecules. https:\/\/doi.org\/10.3390\/molecules29245955","journal-title":"Molecules"},{"issue":"11","key":"5493_CR83","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.2337\/dc18-0049","volume":"41","author":"AV Mathew","year":"2018","unstructured":"Mathew AV et al (2018) Therapeutic lifestyle changes improve HDL function by inhibiting myeloperoxidase-mediated oxidation in patients with metabolic syndrome. Diabetes Care 41(11):2431\u20132437","journal-title":"Diabetes Care"},{"issue":"6","key":"5493_CR84","doi-asserted-by":"publisher","first-page":"4068","DOI":"10.3390\/nu7064068","volume":"7","author":"JM Lou-Bonafonte","year":"2015","unstructured":"Lou-Bonafonte JM et al (2015) PON1 and Mediterranean diet. Nutrients 7(6):4068\u20134092","journal-title":"Nutrients"},{"issue":"24","key":"5493_CR85","doi-asserted-by":"publisher","first-page":"e2920","DOI":"10.1212\/WNL.0000000000012067","volume":"96","author":"T Ballarini","year":"2021","unstructured":"Ballarini T et al (2021) Mediterranean diet, Alzheimer disease biomarkers and brain atrophy in old age. Neurology 96(24):e2920\u2013e2932","journal-title":"Neurology"},{"key":"5493_CR86","doi-asserted-by":"crossref","unstructured":"Reichert CO, Levy D, Bydlowski SP,\u00a0(2020) Paraoxonase role in human neurodegenerative diseases.\u00a0Antioxid 10(1):11","DOI":"10.3390\/antiox10010011"},{"issue":"2","key":"5493_CR87","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.atherosclerosis.2013.03.005","volume":"228","author":"S Aharoni","year":"2013","unstructured":"Aharoni S, Aviram M, Fuhrman B (2013) Paraoxonase 1 (PON1) reduces macrophage inflammatory responses. Atherosclerosis 228(2):353\u2013361","journal-title":"Atherosclerosis"},{"issue":"1\u20132","key":"5493_CR88","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.lfs.2011.10.018","volume":"90","author":"S Loued","year":"2012","unstructured":"Loued S et al (2012) The anti-inflammatory effect of paraoxonase 1 against oxidized lipids depends on its association with high density lipoproteins. Life Sci 90(1\u20132):82\u201388","journal-title":"Life Sci"},{"issue":"1","key":"5493_CR89","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6695796","volume":"2021","author":"F Zimetti","year":"2021","unstructured":"Zimetti F, Adorni MP, Marsillach J, Marchi C, Trentini A, Valacchi G, Cervellati C (2021) Connection between the altered HDL antioxidant and anti-inflammatory properties and the risk to develop Alzheimer\u2019s disease: a narrative review. Oxid Med Cell Longev 2021(1):6695796. https:\/\/doi.org\/10.1155\/2021\/6695796","journal-title":"Oxid Med Cell Longev"},{"issue":"5","key":"5493_CR90","doi-asserted-by":"publisher","DOI":"10.3390\/antiox9050456","volume":"9","author":"A Romani","year":"2020","unstructured":"Romani A et al (2020) Arylesterase activity of paraoxonase-1 in serum and cerebrospinal fluid of patients with Alzheimer\u2019s disease and vascular dementia. Antioxidants 9(5):456","journal-title":"Antioxidants"},{"issue":"1","key":"5493_CR91","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/j.1749-6632.2002.tb04802.x","volume":"977","author":"TF Dantoine","year":"2002","unstructured":"Dantoine TF et al (2002) Paraoxonase 1 activity: a new vascular marker of dementia? Ann N Y Acad Sci 977(1):96\u2013101","journal-title":"Ann N Y Acad Sci"},{"key":"5493_CR92","doi-asserted-by":"crossref","unstructured":"Varlibas F et al\u00a0(2020) Serum HDL associated antioxidant activity in alzheimer's disease: paraoxonase1 and dysfunctional HDL.\u00a0Clin Lab\u00a0 66(9)","DOI":"10.7754\/Clin.Lab.2020.200516"},{"issue":"12","key":"5493_CR93","doi-asserted-by":"publisher","DOI":"10.3390\/antiox9121224","volume":"9","author":"J Marsillach","year":"2020","unstructured":"Marsillach J et al (2020) HDL proteome and Alzheimer\u2019s disease: evidence of a link. Antioxidants 9(12):1224","journal-title":"Antioxidants"},{"issue":"9","key":"5493_CR94","doi-asserted-by":"publisher","DOI":"10.3390\/biom10091276","volume":"10","author":"D Chernick","year":"2020","unstructured":"Chernick D, Zhong R, Li L (2020) The role of HDL and HDL mimetic peptides as potential therapeutics for Alzheimer\u2019s disease. Biomolecules 10(9):1276","journal-title":"Biomolecules"},{"issue":"6","key":"5493_CR95","doi-asserted-by":"publisher","DOI":"10.3390\/nu13062118","volume":"13","author":"AM Dimache","year":"2021","unstructured":"Dimache AM et al (2021) The role of high triglycerides level in predicting cognitive impairment: a review of current evidence. Nutrients 13(6):2118","journal-title":"Nutrients"},{"issue":"23","key":"5493_CR96","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1161\/CIRCULATIONAHA.120.044221","volume":"143","author":"A Rohatgi","year":"2021","unstructured":"Rohatgi A et al (2021) HDL in the 21st century: a multifunctional roadmap for future HDL research. Circulation 143(23):2293\u20132309","journal-title":"Circulation"},{"issue":"9","key":"5493_CR97","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.2174\/0929867325666180530110543","volume":"26","author":"A Pirillo","year":"2019","unstructured":"Pirillo A, Catapano AL, Norata GD (2019) Biological consequences of dysfunctional HDL. Curr Med Chem 26(9):1644\u20131664","journal-title":"Curr Med Chem"},{"key":"5493_CR98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-019-0497-9","volume":"11","author":"EB Button","year":"2019","unstructured":"Button EB et al (2019) ApoA-I deficiency increases cortical amyloid deposition, cerebral amyloid angiopathy, cortical and hippocampal astrogliosis, and amyloid-associated astrocyte reactivity in APP\/PS1 mice. Alzheimers Res Ther 11:1\u201318","journal-title":"Alzheimers Res Ther"},{"key":"5493_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpc.2021.106699","volume":"280","author":"E Lewkowicz","year":"2022","unstructured":"Lewkowicz E, Gursky O (2022) Dynamic protein structures in normal function and pathologic misfolding in systemic amyloidosis. Biophys Chem 280:106699. https:\/\/doi.org\/10.1016\/j.bpc.2021.106699","journal-title":"Biophys Chem"},{"issue":"10","key":"5493_CR100","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25102439","volume":"25","author":"L Ciccone","year":"2020","unstructured":"Ciccone L et al (2020) The positive side of the Alzheimer\u2019s disease amyloid cross-interactions: the case of the A\u03b2 1\u201342 peptide with Tau, TTR, CysC, and ApoA1. Molecules 25(10):2439","journal-title":"Molecules"},{"issue":"2","key":"5493_CR101","doi-asserted-by":"publisher","first-page":"687","DOI":"10.3233\/JAD-151068","volume":"56","author":"RE Slot","year":"2017","unstructured":"Slot RE et al (2017) Apolipoprotein A1 in cerebrospinal fluid and plasma and progression to Alzheimer\u2019s disease in non-demented elderly. J Alzheimers Dis 56(2):687\u2013697","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"5493_CR102","doi-asserted-by":"publisher","DOI":"10.3390\/cells12050746","volume":"12","author":"\u0141 Witucki","year":"2023","unstructured":"Witucki \u0141, Jakubowski H (2023) Depletion of paraoxonase 1 (Pon1) dysregulates mTOR, autophagy, and accelerates amyloid beta accumulation in mice. Cells 12(5):746","journal-title":"Cells"},{"issue":"9","key":"5493_CR103","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1002\/iub.2324","volume":"72","author":"MS Uddin","year":"2020","unstructured":"Uddin MS et al (2020) Multifarious roles of mTOR signaling in cognitive aging and cerebrovascular dysfunction of Alzheimer\u2019s disease. IUBMB Life 72(9):1843\u20131855","journal-title":"IUBMB Life"},{"issue":"7","key":"5493_CR104","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1080\/15548627.2024.2315893","volume":"20","author":"HM Al-Kuraishy","year":"2024","unstructured":"Al-Kuraishy HM et al (2024) Defective autophagy and autophagy activators in myasthenia gravis: a rare entity and unusual scenario. Autophagy 20(7):1473\u20131482","journal-title":"Autophagy"},{"issue":"1","key":"5493_CR105","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s10020-023-00742-2","volume":"29","author":"NH Ali","year":"2023","unstructured":"Ali NH et al (2023) Autophagy and autophagy signaling in epilepsy: possible role of autophagy activator. Mol Med 29(1):142","journal-title":"Mol Med"},{"issue":"2","key":"5493_CR106","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/15548627.2023.2259281","volume":"20","author":"HM Al-Kuraishy","year":"2024","unstructured":"Al-Kuraishy HM et al (2024) The beneficial role of autophagy in multiple sclerosis: yes or no? Autophagy 20(2):259\u2013274","journal-title":"Autophagy"},{"key":"5493_CR107","doi-asserted-by":"publisher","DOI":"10.1080\/15548627.2025.2506292","author":"HM Al-Kuraishy","year":"2025","unstructured":"Al-Kuraishy HM et al (2025) Epilepsy and autophagy modulators: a therapeutic split. Autophagy. https:\/\/doi.org\/10.1080\/15548627.2025.2506292","journal-title":"Autophagy"},{"key":"5493_CR108","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.1065183","volume":"14","author":"Z Wang","year":"2023","unstructured":"Wang Z et al (2023) Microglial autophagy in Alzheimer\u2019s disease and Parkinson\u2019s disease. Front Aging Neurosci 14:1065183","journal-title":"Front Aging Neurosci"},{"issue":"2","key":"5493_CR109","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3233\/JAD-2012-111940","volume":"30","author":"K Borowczyk","year":"2012","unstructured":"Borowczyk K, Shih DM, Jakubowski H (2012) Metabolism and neurotoxicity of homocysteine thiolactone in mice: evidence for a protective role of paraoxonase 1. J Alzheimers Dis 30(2):225\u2013231","journal-title":"J Alzheimers Dis"},{"issue":"6","key":"5493_CR110","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1007\/s10571-023-01350-8","volume":"43","author":"HM Al-Kuraishy","year":"2023","unstructured":"Al-Kuraishy HM et al (2023) Parkinson\u2019s disease risk and hyperhomocysteinemia: the possible link. Cell Mol Neurobiol 43(6):2743\u20132759","journal-title":"Cell Mol Neurobiol"},{"issue":"1","key":"5493_CR111","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3233\/JAD-132714","volume":"42","author":"J Suszy\u0144ska-Zajczyk","year":"2014","unstructured":"Suszy\u0144ska-Zajczyk J et al (2014) Inactivation of the paraoxonase 1 gene affects the expression of mouse brain proteins involved in neurodegeneration. J Alzheimers Dis 42(1):247\u2013260","journal-title":"J Alzheimers Dis"},{"issue":"9","key":"5493_CR112","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0239738","volume":"15","author":"O Kofman","year":"2020","unstructured":"Kofman O et al (2020) Developmental and social deficits and enhanced sensitivity to prenatal chlorpyrifos in PON1-\/- mouse pups and adults. PLoS ONE 15(9):e0239738","journal-title":"PLoS ONE"},{"key":"5493_CR113","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23052687","author":"M Michailidis","year":"2022","unstructured":"Michailidis M et al (2022) Alzheimer\u2019s disease as type 3 diabetes: common pathophysiological mechanisms between Alzheimer\u2019s disease and type 2 diabetes. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23052687","journal-title":"Int J Mol Sci"},{"issue":"3","key":"5493_CR114","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s13410-022-01096-x","volume":"43","author":"U Sar\u0131kaya","year":"2023","unstructured":"Sar\u0131kaya U et al (2023) Could the PON1 phenotype play a key role in insulin resistance? Int J Diabetes Dev Ctries 43(3):476\u2013481","journal-title":"Int J Diabetes Dev Ctries"},{"issue":"1","key":"5493_CR115","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.atherosclerosis.2013.03.028","volume":"229","author":"M Koren-Gluzer","year":"2013","unstructured":"Koren-Gluzer M, Aviram M, Hayek T (2013) Paraoxonase1 (PON1) reduces insulin resistance in mice fed a high-fat diet, and promotes GLUT4 overexpression in myocytes, via the IRS-1\/Akt pathway. Atherosclerosis 229(1):71\u201378","journal-title":"Atherosclerosis"},{"issue":"3","key":"5493_CR116","doi-asserted-by":"publisher","first-page":"239","DOI":"10.4103\/bbrj.bbrj_44_20","volume":"4","author":"HM Al-Kuraishy","year":"2020","unstructured":"Al-Kuraishy HM, Al-Gareeb AI, Naji MT (2020) Brain natriuretic peptide in patients with acute ischemic stroke: role of statins. Biomed Biotechnol Research Journal (BBRJ) 4(3):239\u2013245","journal-title":"Biomed Biotechnol Research Journal (BBRJ)"},{"issue":"2","key":"5493_CR117","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.1063","volume":"11","author":"HM Al\u2010kuraishy","year":"2023","unstructured":"Al\u2010kuraishy HM, Al\u2010Gareeb AI, Alexiou A, Papadakis M, Alsayegh AA, Almohmadi NH, Saad HM, Batiha G-S (2023) Pros and cons for statins use and risk of Parkinson\u2019s disease: an updated perspective. Pharmacol Res Perspect 11(2):e01063. https:\/\/doi.org\/10.1002\/prp2.1063","journal-title":"Pharmacol Res Perspect"},{"key":"5493_CR118","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1007\/s10072-020-04243-6","volume":"41","author":"K Xuan","year":"2020","unstructured":"Xuan K et al (2020) The efficacy of statins in the treatment of Alzheimer\u2019s disease: a meta-analysis of randomized controlled trial. Neurol Sci 41:1391\u20131404","journal-title":"Neurol Sci"},{"issue":"1","key":"5493_CR119","doi-asserted-by":"publisher","first-page":"15280","DOI":"10.1038\/s41598-021-94803-3","volume":"11","author":"S-M Jeong","year":"2021","unstructured":"Jeong S-M et al (2021) Association between statin use and Alzheimer\u2019s disease with dose response relationship. Sci Rep 11(1):15280","journal-title":"Sci Rep"},{"issue":"5","key":"5493_CR120","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S1734-1140(09)70146-X","volume":"61","author":"A Nagila","year":"2009","unstructured":"Nagila A et al (2009) Effect of atorvastatin on paraoxonase1 (PON1) and oxidative status. Pharmacol Rep 61(5):892\u2013898","journal-title":"Pharmacol Rep"},{"issue":"4","key":"5493_CR121","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/S1995-7645(10)60075-2","volume":"3","author":"A Kumar","year":"2010","unstructured":"Kumar A (2010) Effect of simvastatin on paraoxonase 1 (PON1) activity and oxidative stress. Asian Pac J Trop Med 3(4):310\u2013314","journal-title":"Asian Pac J Trop Med"},{"issue":"8","key":"5493_CR122","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1185\/030079904125004394","volume":"20","author":"G Paragh","year":"2004","unstructured":"Paragh G et al (2004) Effect of short term treatment with simvastatin and atorvastatin on lipids and paraoxonase activity in patients with hyperlipoproteinaemia. Curr Med Res Opin 20(8):1321\u20131327","journal-title":"Curr Med Res Opin"},{"key":"5493_CR123","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.plipres.2015.08.003","volume":"60","author":"G Ferretti","year":"2015","unstructured":"Ferretti G, Bacchetti T, Sahebkar A (2015) Effect of statin therapy on paraoxonase-1 status: a systematic review and meta-analysis of 25 clinical trials. Prog Lipid Res 60:50\u201373","journal-title":"Prog Lipid Res"},{"issue":"12","key":"5493_CR124","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1111\/1753-0407.13334","volume":"14","author":"HM Al-kuraishy","year":"2022","unstructured":"Al-kuraishy HM et al (2022) Metformin and growth differentiation factor 15 (GDF15) in type 2 diabetes mellitus: a hidden treasure. J Diabetes 14(12):806\u2013814","journal-title":"J Diabetes"},{"issue":"11","key":"5493_CR125","doi-asserted-by":"publisher","DOI":"10.3390\/ph15111361","volume":"15","author":"HM Al-Kuraishy","year":"2022","unstructured":"Al-Kuraishy HM et al (2022) Potential therapeutic benefits of metformin alone and in combination with sitagliptin in the management of type 2 diabetes patients with COVID-19. Pharmaceuticals 15(11):1361","journal-title":"Pharmaceuticals"},{"key":"5493_CR126","doi-asserted-by":"publisher","first-page":"108966","DOI":"10.1016\/j.neuropharm.2022.108966","volume":"207","author":"P Ning","year":"2022","unstructured":"Ning P et al (2022) Exploring the dual character of metformin in Alzheimer\u2019s disease. Neuropharmacology 207:108966","journal-title":"Neuropharmacology"},{"issue":"4","key":"5493_CR127","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.3233\/JAD-220180","volume":"88","author":"A Luo","year":"2022","unstructured":"Luo A et al (2022) Association between metformin and Alzheimer\u2019s disease: a systematic review and meta-analysis of clinical observational studies. J Alzheimers Dis 88(4):1311\u20131323","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"5493_CR128","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s10787-023-01163-7","volume":"31","author":"HM Al-Kuraishy","year":"2023","unstructured":"Al-Kuraishy HM et al (2023) Long-term use of metformin and Alzheimer\u2019s disease: beneficial or detrimental effects. Inflammopharmacology 31(3):1107\u20131115","journal-title":"Inflammopharmacology"},{"issue":"4","key":"5493_CR129","doi-asserted-by":"publisher","first-page":"e963","DOI":"10.1210\/clinem\/dgz234","volume":"105","author":"JK Sluggett","year":"2020","unstructured":"Sluggett JK et al (2020) Metformin and risk of Alzheimer\u2019s disease among community-dwelling people with diabetes: a national case-control study. J Clin Endocrinol Metab 105(4):e963\u2013e972","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"5493_CR130","doi-asserted-by":"publisher","DOI":"10.3390\/ph14090890","volume":"14","author":"SR Poor","year":"2021","unstructured":"Poor SR et al (2021) Metformin a potential pharmacological strategy in late onset Alzheimer\u2019s disease treatment. Pharmaceuticals 14(9):890","journal-title":"Pharmaceuticals"},{"issue":"3","key":"5493_CR131","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.1752-8062.2012.00391.x","volume":"5","author":"E Meaney","year":"2012","unstructured":"Meaney E et al (2012) Does metformin increase paraoxonase activity in patients with the metabolic syndrome? Additional data from the MEFISTO study. Clin Transl Sci 5(3):265\u2013268","journal-title":"Clin Transl Sci"},{"issue":"2","key":"5493_CR132","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2014.05.569","volume":"235","author":"I Fort","year":"2014","unstructured":"Fort I et al (2014) Effects of metformin in paraoxonase-1 deficient mice. Atherosclerosis 235(2):e193","journal-title":"Atherosclerosis"},{"key":"5493_CR133","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.cbi.2016.03.004","volume":"249","author":"A Garc\u00eda-Heredia","year":"2016","unstructured":"Garc\u00eda-Heredia A et al (2016) Metformin administration induces hepatotoxic effects in paraoxonase-1-deficient mice. Chem Biol Interact 249:56\u201363","journal-title":"Chem Biol Interact"},{"key":"5493_CR134","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13098-019-0431-0","volume":"11","author":"DF Roxo","year":"2019","unstructured":"Roxo DF et al (2019) Curcumin combined with metformin decreases glycemia and dyslipidemia, and increases paraoxonase activity in diabetic rats. Diabetol Metab Syndr 11:1\u20138","journal-title":"Diabetol Metab Syndr"},{"issue":"10","key":"5493_CR135","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s00011-022-01615-w","volume":"71","author":"SS Alkhayyat","year":"2022","unstructured":"Alkhayyat SS, Al-kuraishy HM, Al-Gareeb AI, El-Bouseary MM, AboKamer AM, Batiha G-S, Simal-Gandara J (2022) Fenofibrate for COVID-19 and related complications as an approach to improve treatment outcomes: the missed key for Holy Grail. Inflamm Res 71(10):1159\u20131167. https:\/\/doi.org\/10.1007\/s00011-022-01615-w","journal-title":"Inflamm Res"},{"issue":"3","key":"5493_CR136","doi-asserted-by":"publisher","first-page":"259","DOI":"10.4103\/bbrj.bbrj_26_20","volume":"4","author":"HA Rasheed","year":"2020","unstructured":"Rasheed HA et al (2020) Fenofibrate and Crataegus oxyacantha is an effectual combo for mixed dyslipidemia. Biomed Biotechnol Res J (BBRJ) 4(3):259\u2013265","journal-title":"Biomed Biotechnol Res J (BBRJ)"},{"issue":"5","key":"5493_CR137","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s40256-023-00593-6","volume":"23","author":"MS Khan","year":"2023","unstructured":"Khan MS et al (2023) Efficacy of pemafibrate versus fenofibrate administration on serum lipid levels in patients with dyslipidemia: network meta-analysis and systematic review. Am J Cardiovasc Drugs 23(5):547\u2013558","journal-title":"Am J Cardiovasc Drugs"},{"issue":"5","key":"5493_CR138","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1007\/s11064-020-02993-5","volume":"45","author":"S W\u00f3jtowicz","year":"2020","unstructured":"W\u00f3jtowicz S et al (2020) The novel role of PPAR alpha in the brain: promising target in therapy of Alzheimer\u2019s disease and other neurodegenerative disorders. Neurochem Res 45(5):972\u2013988","journal-title":"Neurochem Res"},{"key":"5493_CR139","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ijdevneu.2014.10.004","volume":"38","author":"H Zhang","year":"2014","unstructured":"Zhang H et al (2014) Fenofibrate reduces amyloidogenic processing of APP in APP\/PS1 transgenic mice via PPAR-\u03b1\/PI3-K pathway. Int J Dev Neurosci 38:223\u2013231","journal-title":"Int J Dev Neurosci"},{"key":"5493_CR140","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2019.109793","volume":"97","author":"N Assaf","year":"2020","unstructured":"Assaf N et al (2020) Neuroprotective effect of PPAR alpha and gamma agonists in a mouse model of amyloidogenesis through modulation of the Wnt\/beta catenin pathway via targeting alpha-and beta-secretases. Prog Neuropsychopharmacol Biol Psychiatry 97:109793","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"19","key":"5493_CR141","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.1021\/bi400377p","volume":"52","author":"CJ Crump","year":"2013","unstructured":"Crump CJ, Johnson DS, Li Y-M (2013) Development and mechanism of \u03b3-secretase modulators for Alzheimer\u2019s disease. Biochemistry 52(19):3197\u20133216","journal-title":"Biochemistry"},{"issue":"3","key":"5493_CR142","first-page":"463","volume":"53","author":"J Be","year":"2002","unstructured":"Be J et al (2002) The effect of peroxisome proliferator-activated receptors \u03b1 (PPAR\u03b1) agonist, fenofibrate, on lipid peroxidation, total antioxidant capacity, and plasma paraoxonase 1 (PON1) activity. Journal of Physiology and Pharmacology 53(3):463\u2013475","journal-title":"Journal of Physiology and Pharmacology"},{"issue":"1","key":"5493_CR143","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.atherosclerosis.2007.03.001","volume":"196","author":"W Phuntuwate","year":"2008","unstructured":"Phuntuwate W et al (2008) Effect of fenofibrate therapy on paraoxonase1 status in patients with low HDL-C levels. Atherosclerosis 196(1):122\u2013128","journal-title":"Atherosclerosis"},{"issue":"5","key":"5493_CR144","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.metabol.2016.01.002","volume":"65","author":"A Sahebkar","year":"2016","unstructured":"Sahebkar A et al (2016) Systematic review and meta-analysis deciphering the impact of fibrates on paraoxonase-1 status. Metabolism 65(5):609\u2013622","journal-title":"Metabolism"},{"issue":"11","key":"5493_CR145","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1345\/aph.1Q238","volume":"45","author":"BW Miller","year":"2011","unstructured":"Miller BW, Willett KC, Desilets AR (2011) Rosiglitazone and pioglitazone for the treatment of Alzheimer\u2019s disease. Ann Pharmacother 45(11):1416\u20131424","journal-title":"Ann Pharmacother"},{"issue":"4","key":"5493_CR146","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/sj.tpj.6500369","volume":"6","author":"M Risner","year":"2006","unstructured":"Risner M et al (2006) Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer\u2019s disease. Pharmacogenomics J 6(4):246\u2013254","journal-title":"Pharmacogenomics J"},{"issue":"11","key":"5493_CR147","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1176\/appi.ajgp.13.11.950","volume":"13","author":"GS Watson","year":"2005","unstructured":"Watson GS (2005) Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 13(11):950\u2013958. https:\/\/doi.org\/10.1176\/appi.ajgp.13.11.950","journal-title":"Am J Geriatr Psychiatry"},{"key":"5493_CR148","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.666958","volume":"15","author":"AM Saunders","year":"2021","unstructured":"Saunders AM, Burns DK, Gottschalk WK (2021) Reassessment of pioglitazone for Alzheimer\u2019s disease. Front Neurosci 15:666958. https:\/\/doi.org\/10.3389\/fnins.2021.666958","journal-title":"Front Neurosci"},{"issue":"5","key":"5493_CR149","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1159\/000510677","volume":"49","author":"M Mu\u00f1oz-Jim\u00e9nez","year":"2021","unstructured":"Mu\u00f1oz-Jim\u00e9nez M et al (2021) Antidiabetic drugs in Alzheimer\u2019s disease and mild cognitive impairment: a systematic review. Dement Geriatr Cogn Disord 49(5):423\u2013434","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"12","key":"5493_CR150","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1111\/j.1440-1681.2006.04505.x","volume":"33","author":"J Van Wijk","year":"2006","unstructured":"Van Wijk J, Coll B, Cabezas MC, Koning E, Camps J, Rabelink T, Mackness B, Joven J (2006) Rosiglitazone modulates fasting and post\u2010prandial paraoxonase 1 activity in type 2 diabetic patients. Clin Exp Pharmacol Physiol 33(12):1134\u20131137. https:\/\/doi.org\/10.1111\/j.1440-1681.2006.04505.x","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"5493_CR151","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1590\/1414-431X20132818","volume":"46","author":"Y Atamer","year":"2013","unstructured":"Atamer Y et al (2013) Effects of rosiglitazone on serum paraoxonase activity and metabolic parameters in patients with type 2 diabetes mellitus. Braz J Med Biol Res 46:528\u2013532","journal-title":"Braz J Med Biol Res"},{"issue":"2","key":"5493_CR152","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1017\/S0007114510004356","volume":"105","author":"C Schrader","year":"2011","unstructured":"Schrader C et al (2011) Curcumin induces paraoxonase 1 in cultured hepatocytes in vitro but not in mouse liver in vivo. Br J Nutr 105(2):167\u2013170","journal-title":"Br J Nutr"},{"issue":"5","key":"5493_CR153","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1515\/jbcpp-2020-0067","volume":"32","author":"A Khodarahmi","year":"2021","unstructured":"Khodarahmi A et al (2021) Curcumin exerts hepatoprotection via overexpression of Paraoxonase-1 and its regulatory genes in rats undergone bile duct ligation. J Basic Clin Physiol Pharmacol 32(5):969\u2013977","journal-title":"J Basic Clin Physiol Pharmacol"},{"issue":"5","key":"5493_CR154","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s00702-022-02480-x","volume":"129","author":"X Zhou","year":"2022","unstructured":"Zhou X, Venigalla M, Raju R, M\u00fcnch G (2022) Pharmacological considerations for treating neuroinflammation with curcumin in Alzheimer\u2019s disease. J Neural Transm 129(5):755\u2013771. https:\/\/doi.org\/10.1007\/s00702-022-02480-x","journal-title":"J Neural Transm"},{"issue":"12","key":"5493_CR155","doi-asserted-by":"publisher","DOI":"10.3390\/ma14123332","volume":"14","author":"D Ege","year":"2021","unstructured":"Ege D (2021) Action mechanisms of curcumin in Alzheimer\u2019s disease and its brain targeted delivery. Materials 14(12):3332","journal-title":"Materials"},{"issue":"4","key":"5493_CR156","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.nut.2009.05.003","volume":"26","author":"B Fuhrman","year":"2010","unstructured":"Fuhrman B, Volkova N, Aviram M (2010) Pomegranate juice polyphenols increase recombinant paraoxonase-1 binding to high-density lipoprotein: studies in vitro and in diabetic patients. Nutrition 26(4):359\u2013366","journal-title":"Nutrition"},{"key":"5493_CR157","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctim.2019.102252","volume":"48","author":"M Morvaridzadeh","year":"2020","unstructured":"Morvaridzadeh M et al (2020) The effect of pomegranate on oxidative stress parameters: a systematic review and meta-analysis. Complement Ther Med 48:102252","journal-title":"Complement Ther Med"},{"issue":"7","key":"5493_CR158","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1016\/j.sjbs.2020.04.045","volume":"27","author":"MS Almuhayawi","year":"2020","unstructured":"Almuhayawi MS et al (2020) The potential role of pomegranate and its nano-formulations on cerebral neurons in aluminum chloride induced Alzheimer rat model. Saudi J Biol Sci 27(7):1710\u20131716","journal-title":"Saudi J Biol Sci"},{"issue":"1","key":"5493_CR159","first-page":"99","volume":"61","author":"C Boesch-Saadatmandi","year":"2010","unstructured":"Boesch-Saadatmandi C et al (2010) Effect of quercetin on paraoxonase 1 activity\u2014studies in cultured cells, mice and humans. J Physiol Pharmacol 61(1):99","journal-title":"J Physiol Pharmacol"},{"issue":"4","key":"5493_CR160","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.bbrc.2009.01.015","volume":"379","author":"M Gong","year":"2009","unstructured":"Gong M et al (2009) Quercetin up-regulates paraoxonase 1 gene expression with concomitant protection against LDL oxidation. Biochem Biophys Res Commun 379(4):1001\u20131004","journal-title":"Biochem Biophys Res Commun"},{"key":"5493_CR161","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.lfs.2019.03.055","volume":"224","author":"E Zaplatic","year":"2019","unstructured":"Zaplatic E et al (2019) Molecular mechanisms underlying protective role of quercetin in attenuating Alzheimer\u2019s disease. Life Sci 224:109\u2013119","journal-title":"Life Sci"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05493-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-025-05493-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05493-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T12:02:42Z","timestamp":1764763362000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-025-05493-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":161,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["5493"],"URL":"https:\/\/doi.org\/10.1007\/s12035-025-05493-1","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"assertion":[{"value":"1 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"244"}}